Rubicon Research Limited has scheduled an earnings conference call to discuss its financial performance for the quarter and year ended March 31, 2026. The meeting is set to take place on Friday, May 29, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Management Representation

The conference call will be represented by the company's senior management team. Key participants include Mr. Parag Sancheti, CEO; Mr. Nitin Jajodia, CFO; and Mr. Sagar Oak, SVP Corp. Dev & Strategy. The session will provide insights into the financial results and the company's strategic way forward.

Call Schedule and Access

The earnings call is scheduled for May 29, 2026, with specific timings allocated for different regions to facilitate global participation. The call will be led by Tushar Manudhane, Executive Director – Healthcare at Motilal Oswal Financial Services.

Participants can join the conference using the primary universal numbers: +91 22 6280 1149 or +91 22 7115 8050. International toll-free numbers are also available for the USA (18667462133), UK (08081011573), Singapore (8001012045), and Hong Kong (800964448).

Rubicon Research Limited has completed the acquisition of an 85% stake in Arinna Lifesciences Limited on April 30, 2026. The transaction was executed as a secondary acquisition under the terms agreed in the Share Purchase Agreement, as intimated to the stock exchanges. This development follows the company's earlier communication dated April 15, 2026.

Transaction Details

The acquisition involves the purchase of securities representing an 85% stake in Arinna Lifesciences Limited. The completion of this transaction marks a significant expansion for Rubicon Research Limited in the lifesciences sector. The deal was structured as a secondary acquisition, indicating the purchase of existing shares rather than new issuance.

Subsidiary Status

Following the completion of the acquisition, Arinna Lifesciences Limited has become a subsidiary of Rubicon Research Limited. This change in ownership structure will enable the company to consolidate the operations and financials of Arinna Lifesciences Limited going forward.

Regulatory Compliance

The intimation regarding the completion of this acquisition was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was addressed to both BSE Limited and National Stock Exchange of India Limited, with Rubicon Research Limited listed under scrip code 544578 on BSE and symbol RUBICON on NSE.